AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7033014
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of cyclopenthiazide and oxprenolol (Trasidrex)
Trial: 7033014
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (previous treatment discontinued)
Trial: 30447975
Drug: Lycopene-enriched ice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene-enriched ice cream
Trial: 30447975
Drug: Control ice
RxNorm normalized name: Camphor Ice Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control ice cream
Trial: 22731246
Drug: Bevacizumab (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (1.25 mg/0.1 mL)
Trial: 18997832
Drug: ATL-104 (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATL-104 (50, 100 or 150 mg)
Trial: 17284732
Drug: Unilateral lower
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral lower limb suspension for 4 weeks
Trial: 12362963
Drug: 4 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 sessions of acceptance and commitment therapy (ACT) plus treatment as usual (TAU)
Trial: 9838238
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue (2 ml applied to the axillary dissection area)
Trial: 2650723
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (cisplatinum, bleomycin, vindesine, mitomycin C)
Trial: 17978324
Drug: In-patient psychiatric
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-patient psychiatric treatment
Trial: 17978324
Drug: General out-patient
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General out-patient treatment
Trial: 12790762
Drug: Dosulepine (TCA)
RxNorm normalized name: dosulepin
DrugBank: Dosulepin (DB09167)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosulepine (TCA) at doses of 50-250 mg
Trial: 12790762
Drug: Citalopram (SSRI)
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citalopram (SSRI) at doses of 20-80 mg
Trial: 12790762
Drug: Lithium (Li)
DrugBank: Lithium succinate (DB14508)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (Li) with plasma levels of 0.66±0.08 meq/l
Trial: 11124358
Drug: Medical abortion
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical abortion with methotrexate 50 mg orally followed by misoprostol 800 microg vaginally
Trial: 9614721
Drug: Intrapleural instillation
RxNorm normalized name: Talc Powder for intrapleural instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural instillation of low-dose streptokinase
Trial: 2877571
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg famotidine at bedtime
Trial: 2656335
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg famotidine at bedtime
Trial: 21990397
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + placebo
Trial: 27064031
Drug: Zhuanggu joint
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhuanggu joint capsules combined with celecoxib capsules
Trial: 27064031
Drug: Zhuanggu joint
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhuanggu joint capsules alone
Trial: 27064031
Drug: Celecoxib capsules
RxNorm normalized name: Celecoxib Capsules
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib capsules combined with Zhuanggu joint capsule simulants
Trial: 22186881
Drug: 16 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 sessions of hope‐based substance abuse treatment
Trial: 22186881
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list for another term of treatment
Trial: 20232582
Drug: copper zinc
RxNorm normalized name: copper gluconate / zinc picolinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: copper zinc malonate lotion plus 4% hydroquinone cream (twice daily) and tretinoin cream (once daily)
Trial: 18466615
Drug: Etoricoxib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (all doses combined)
Trial: 2601834
Drug: Permanent subdural
RxNorm normalized name: penicillin G benzathine Prefilled Syringe [Permapen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permanent subdural drain with subcutaneous reservoir
Trial: 29058477
Drug: Injection technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection technique (IT) education with 4-mm pen needle; intensive education and reinforcement for 6 months.
Trial: 26466482
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 9 U rhGH every night for 7 days
Trial: 21841050
Drug: Intravenous parecoxib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous parecoxib, 40 mg i.v.
Trial: 9393568
Drug: Palliative coeliac
RxNorm normalized name: Various pain palliation radiopharmaceuticals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative coeliac axis intra-arterial cyclic infusions (CAI) consisting of mitoxantrone 10 mg/m2 on day 1, folinic acid 170 mg/m2 and 5-FU 600 mg/m2 during days 2-4, and cis-platinum 60 mg/m2 on day 5 for up to 11 cycles.
Trial: 9393568
Drug: Adjuvant coeliac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant coeliac axis intra-arterial cyclic infusions (CAI) consisting of mitoxantrone 10 mg/m2 on day 1, folinic acid 170 mg/m2 and 5-FU 600 mg/m2 during days 2-4, and cis-platinum 60 mg/m2 on day 5 for up to 6 cycles.
Trial: 8322238
Drug: Inhaled methacholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled methacholine with dosimeter method (maximal dose 210 mumol)
Trial: 8322238
Drug: Inhaled methacholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled methacholine with tidal breathing method (730 mumol)
Trial: 2825567
Drug: Beclomethasone aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone aerosol (1 mg bid)
Trial: 2825567
Drug: Slow-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release theophylline (6.5 mg/kg bid)
Trial: 2825567
Drug: Slow-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release verapamil (120 mg bid)
Trial: 2825567
Drug: Cromolyn (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromolyn (20 mg qid via spinhaler)
Trial: 28449627
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg lornoxicam
Trial: 28449627
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg lornoxicam
Trial: 28449627
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (10 ml isotonic 0.9% NaCl solution)
Trial: 19167684
Drug: Platinum-based salvage
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based salvage chemotherapy, high-dose therapy, and autologous stem cell transplantation (ASCT) for PET-positive patients
Trial: 19167684
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for PET-negative patients
Trial: 11311997
Drug: Synthetic, monovalent,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic, monovalent, octameric HIV‐1 MN V3 peptide in aluminum hydroxide (alum) adjuvant administered by intramuscular delivery
Trial: 11311997
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of the vaccine (encapsulated in biodegradable micro‐spheres)
Trial: 11311997
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral administration with parenteral boosting
Trial: 9159559
Drug: Oral lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral lamotrigine monotherapy for up to 48 weeks
Trial: 22806208
Drug: Tamsulosin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.2 mg/day orally for 7 days)
Trial: 8776832
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g pectin
Trial: 8776832
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g pectin
Trial: 8776832
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g pectin
Trial: 29654805
Drug: SER120 intranasal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SER120 intranasal spray 0.83 mcg
Trial: 29654805
Drug: SER120 intranasal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SER120 intranasal spray 1.66 mcg
Trial: 16562807
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (PN) supplemented with glutamine (0.4 g/kg/day of L-alanine-L-glutamine)
Trial: 18596311
Drug: Standard parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard parenteral nutrition (PN)
Trial: 12792701
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg kg‐1 day‐1 ursodeoxycholic acid for three months
Trial: 10234869
Drug: Reflexological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reflexological treatment for headache
Trial: 1655987
Drug: Three or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three or four drugs plus whole-lung irradiation
Trial: 1655987
Drug: Two or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two or three drugs without whole-lung irradiation
Trial: 6661381
Drug: Brotizolam (0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brotizolam (0.50 mg)
Trial: 30698675
Drug: Pre-treatment genotyping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment genotyping (genotype-guided thiopurine dosing)
Trial: 27883215
Drug: Immunomodulator combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulator combination therapy
Trial: 27382454
Drug: Deferasirox (DFX)
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox (DFX) - single oral daily dose of 20-40 mg/kg/day
Trial: 27382454
Drug: Deferoxamine (DFO)
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferoxamine (DFO) - 20-50 mg/kg/day via subcutaneous infusion over 8-10 hours, 5 days a week
Trial: 21878578
Drug: 25 µg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 µg/h reservoir with heat
Trial: 21878578
Drug: 25 µg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 µg/h matrix with heat
Trial: 21878578
Drug: 50 µg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg/h reservoir without heat
Trial: 21878578
Drug: 25 µg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 µg/h reservoir without heat
Trial: 21878578
Drug: 25 µg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 µg/h matrix without heat
Trial: 17205576
Drug: No postsurgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postsurgical treatment
Trial: 15889357
Drug: Telavancin (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telavancin (administered intravenously once daily)
Trial: 15889357
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (antistaphylococcal penicillin 4 times daily or vancomycin twice daily)
Trial: 11281611
Drug: Octreotide (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (0.1 mg sc) during exercise
Trial: 11281611
Drug: Octreotide (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (0.1 mg sc) after exercise
Trial: 11281611
Drug: Octreotide (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (0.1 mg sc) without exercise
Trial: 7942182
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of interferon and ACNU in addition to radiotherapy (IAR therapy)
Trial: 7942182
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy with radiation and chemotherapy
Trial: 2946583
Drug: Prednisone 10
RxNorm normalized name: prednisone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 10 mg X 3 daily
Trial: 2946583
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) orally 500 mg daily
Trial: 2946583
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) i.m. 1000 mg daily for 3 weeks followed by 500 mg i.m. weekly
Trial: 23993028
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume (5 mL/kg + 5 cm H2O positive end-expiratory pressure) preserved ventilation (PV)
Trial: 23993028
Drug: Conventional tidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional tidal volume (8 mL/kg) controlled ventilation (CV)
Trial: 22010223
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg hydrogen sulfide from wk 0 to 3 and 3 mg/kg from wk 4 to 6
Trial: 22010223
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg hydrogen sulfide from wk 0 to 3 and 6 mg/kg from wk 4 to 6
Trial: 22010223
Drug: 8 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/kg hydrogen sulfide from wk 0 to 3 and 12 mg/kg from wk 4 to 6
Trial: 16600069
Drug: Mind Reading
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mind Reading software used at home with weekly tutor sessions
Trial: 1404051
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment of manipulation and application of plaster of Paris
Trial: 7152079
Drug: Alclometasone cream
RxNorm normalized name: alclometasone Topical Cream
DrugBank: Alclometasone (DB00240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alclometasone cream 0.05% applied twice a day for 21 days
Trial: 7152079
Drug: Clobetasone butyrate
RxNorm normalized name: clobetasone butyrate
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Clobetasone butyrate cream 0.5% applied twice a day for 21 days
Trial: 27677487
Drug: Protein-Enriched Diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-Enriched Diet (PED) with protein intake 2.0 g/kg of ideal body weight
Trial: 27677487
Drug: Normal Protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Protein Diet (NPD) with protein intake 1.0 g/kg of ideal body weight
Trial: 27233490
Drug: Anemia (hemoglobin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anemia (hemoglobin level ≤ 6.0 mmol/L or 9.7 g/dL)
Trial: 22833684
Drug: Primary tumour
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary tumour resection plus systemic therapy
Trial: 17064199
Drug: ICA-17043 50
RxNorm normalized name: ICA-105665
DrugBank: ICA-105665 (DB06089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICA-17043 50 mg
Trial: 17064199
Drug: ICA-17043 100
RxNorm normalized name: ICA-105665
DrugBank: ICA-105665 (DB06089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICA-17043 100 mg
Trial: 17064199
Drug: ICA-17043 150
RxNorm normalized name: ICA-105665
DrugBank: ICA-105665 (DB06089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICA-17043 150 mg
Trial: 12588578
Drug: Exercise and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise and incontinence care provided every 2 hours from 8:00 a.m. to 4:30 p.m. (total of four daily care episodes) 5 days a week for 32 weeks
Trial: 8934060
Drug: Norplant implants
RxNorm normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norplant implants users
Trial: 1751913
Drug: Systemic and
RxNorm normalized name: Estradiol and Levonorgestrel Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic and periocular steroid therapy
Trial: 7042090
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with MOPP and ABDV given in alternating months; Radiation therapy (RT) (2000 rad in 2 weeks) during Month 5
Trial: 28821315
Drug: Starch-entrapped microspheres
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch-entrapped microspheres (SM) 9 or 12 g
Trial: 28821315
Drug: Psyllium (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium (12 g)
Trial: 26357934
Drug: Group S
RxNorm normalized name: Blood group substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group S (supine position immediately after injection)
Trial: 24083593
Drug: Treatment Region
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Region (TR)
Trial: 18941065
Drug: Dynamic contrast-enhanced
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic contrast-enhanced MRI before and after two cycles of chemotherapy
Trial: 12508078
Drug: High amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High amino acid intake (HAA) at 3 g.kg(‐1).d(‐1)
Trial: 8558194
Drug: Fluorouracil (5FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil (5FU) based chemotherapy: 200 mg/m2/d for 3 weeks with leucovorin 20 mg/m2/w, plus Cisplatin 100 mg/m2 on day 1
Trial: 8558194
Drug: Fluorouracil (5FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil (5FU) based chemotherapy
Trial: 6630314
Drug: Oral papaverine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral papaverine (600 mg)
Trial: 6630314
Drug: Intravenous papaverine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous papaverine (100 mg)
Trial: 23143142
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT), administered two times per week for 4 weeks, n = 12
Trial: 22947909
Drug: Atorvastatin and
RxNorm normalized name: atorvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin and antihistamines
Trial: 22947909
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and antihistamines (Control group)
Trial: 18926645
Drug: D-amphetamine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-amphetamine (0, 15, and 30 mg/day)
Trial: 18926645
Drug: Cocaine (4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (4, 30, 60 mg, i.n.)
Trial: 18926645
Drug: D-amphetamine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-amphetamine (30 mg/day)
Trial: 18926645
Drug: D-amphetamine (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-amphetamine (0 mg/day)
Trial: 17698275
Drug: Quetiapine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (up to 400 mg/day)
Trial: 15010743
Drug: Warfarin (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (not specified dosage or duration)
Trial: 9203245
Drug: Remacemide hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide hydrochloride (300 mg single dose, 150 mg or 300 mg twice daily for 14 days)
Trial: 9203245
Drug: Remacemide hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide hydrochloride (150 mg twice daily)
Trial: 9203245
Drug: Remacemide hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide hydrochloride (300 mg twice daily)
Trial: 27553205
Drug: Split-dose 2L-PEGA
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose 2L-PEGA
Trial: 27553205
Drug: Single-dose 4L-PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose 4L-PEG
Trial: 27553205
Drug: Split-dose 4L-PEG
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose 4L-PEG
Trial: 23376362
Drug: Peginterferon (PegIFN)
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon (PegIFN) therapy for 52 weeks